PE20230242A1 - Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas - Google Patents

Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas

Info

Publication number
PE20230242A1
PE20230242A1 PE2022001926A PE2022001926A PE20230242A1 PE 20230242 A1 PE20230242 A1 PE 20230242A1 PE 2022001926 A PE2022001926 A PE 2022001926A PE 2022001926 A PE2022001926 A PE 2022001926A PE 20230242 A1 PE20230242 A1 PE 20230242A1
Authority
PE
Peru
Prior art keywords
methods
pharmaceutical compositions
lipoic acid
treatment
same
Prior art date
Application number
PE2022001926A
Other languages
English (en)
Inventor
Christoph Bucher
Dietmar Flubacher
Jeremiah Douglas Foutch
Malay Ghosh
Johannes Franz Kluge
Zaixing Li
Cale Ry Mcalister
Liladhar Murlidhar Waykole
Jens Soren Worthmann
Tingying Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20230242A1 publication Critical patent/PE20230242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgacion proporciona sales de ester de colina de acido lipoico (LACE), sus formas cristalinas, y metodos de uso. La presente divulgacion ademas proporciona composiciones farmaceuticas de sales de LACE y sus metodos de uso.
PE2022001926A 2020-03-13 2021-03-12 Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas PE20230242A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020079271 2020-03-13
US202063013836P 2020-04-22 2020-04-22
PCT/IB2021/052092 WO2021181361A1 (en) 2020-03-13 2021-03-12 Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

Publications (1)

Publication Number Publication Date
PE20230242A1 true PE20230242A1 (es) 2023-02-07

Family

ID=75108681

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001926A PE20230242A1 (es) 2020-03-13 2021-03-12 Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas

Country Status (18)

Country Link
US (2) US11135239B1 (es)
EP (1) EP4118079A1 (es)
JP (2) JP7041298B2 (es)
KR (1) KR20220146561A (es)
CN (2) CN113387923A (es)
AU (1) AU2021235563A1 (es)
BR (1) BR112022018043A2 (es)
CA (1) CA3175077A1 (es)
CO (1) CO2022012653A2 (es)
CR (1) CR20220449A (es)
DO (1) DOP2022000179A (es)
EC (1) ECSP22069611A (es)
IL (1) IL295378A (es)
JO (1) JOP20220211A1 (es)
MX (1) MX2022011206A (es)
PE (1) PE20230242A1 (es)
TW (1) TWI768760B (es)
WO (1) WO2021181361A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520920A (en) 1978-07-31 1980-02-14 Honda Motor Co Ltd Device for absorbing twisting vibration of drive system
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
PL2442647T3 (pl) 2009-06-15 2016-09-30 Związki ditiolowe, pochodne i ich zastosowania
MX2016011290A (es) * 2014-03-03 2017-04-27 Encore Vision Inc Composiciones de ester de colina de acido lipoico y metodos de uso.
WO2016126662A1 (en) 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CA3022351A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
US20190022059A1 (en) * 2015-09-24 2019-01-24 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JOP20190057A1 (ar) 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
SG11202006492SA (en) * 2018-02-05 2020-08-28 Cellix Bio Private Ltd Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
US11158871B2 (en) 2018-07-18 2021-10-26 GM Global Technology Operations LLC Fuel cell assembly and a vehicle that utilizes the fuel cell assembly
US11985964B2 (en) 2018-08-03 2024-05-21 Kevin F Lohmeier Fishing rod holder
CN108822077A (zh) 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法
CN108586429A (zh) 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法

Also Published As

Publication number Publication date
CA3175077A1 (en) 2021-09-16
ECSP22069611A (es) 2022-10-31
CN115279745A (zh) 2022-11-01
CO2022012653A2 (es) 2022-09-09
CN113387923A (zh) 2021-09-14
US20210393671A1 (en) 2021-12-23
IL295378A (en) 2022-10-01
TW202140435A (zh) 2021-11-01
KR20220146561A (ko) 2022-11-01
BR112022018043A2 (pt) 2022-10-18
WO2021181361A1 (en) 2021-09-16
CR20220449A (es) 2022-10-12
JP2021147392A (ja) 2021-09-27
US11135239B1 (en) 2021-10-05
EP4118079A1 (en) 2023-01-18
US20210283171A1 (en) 2021-09-16
US11590158B2 (en) 2023-02-28
JOP20220211A1 (ar) 2023-01-30
TWI768760B (zh) 2022-06-21
DOP2022000179A (es) 2022-09-30
MX2022011206A (es) 2022-09-19
JP2022058376A (ja) 2022-04-12
JP7041298B2 (ja) 2022-03-23
AU2021235563A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2019002664A1 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados.
GT201400281A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
UY33270A (es) Sales cristalinas de un potente inhibidor del hcv
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CO2021011042A2 (es) Sales de sulcardina
UY39390A (es) Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo
CO2022015157A2 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
PE20230242A1 (es) Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas
CL2023001230A1 (es) Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos